Biotech upstart raises $10.5M for MRSA antibody

Hoping to thrive in a development arena long neglected by Big Pharma, Woburn, MA-based Excelimmune has raised $10.5 million in a Series B to fund its work on an antibody candidate targeting MRSA. The round was provided by a group of unnamed "high net worth" angel investors. "The continued support from investors underscores the significant potential of our unique HRPA approach to treating nosocomial infectious disease," said Quinton Zondervan, the CEO of Excelimmune. "In addition to doubling Excelimmune's size over the past year, this funding provides us with the capital required to enter the next stage of our product and technology development." Excelimmune release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.